TY - JOUR
T1 - Costs of running a universal adolescent hepatitis B vaccination programme
AU - Wallace, L. A.
AU - Young, D.
AU - Brown, A.
AU - Cameron, J. C.
AU - Ahmed, S.
AU - Duff, R.
AU - Carman, W. F.
AU - Kitchin, N. R.E.
AU - Nguyen-Van-Tam, J. S.
AU - Goldberg, D. J.
N1 - Funding Information:
We gratefully acknowledge the financial support from Aventis Pasteur MSD (now Sanofi Pasteur MSD).
PY - 2005/12/1
Y1 - 2005/12/1
N2 - In the first UK study to examine feasibility and acceptability of universal adolescent hepatitis B vaccination, the costs associated with the administration and uptake (80.2 and 89.3% for three doses and at least two doses, respectively), of a three-dose regimen in pupils in Glasgow schools (2001/2002) were measured. These data were used to estimate the economic outlay for the delivery of a routine, ongoing three-dose and two-dose hepatitis B vaccine programme in schools. Vaccine, accounting for almost 70% of the overall costs, was the largest cost item for both the pilot and routine programmes, using either regimen. However, the ongoing, two-dose regimen was the cheapest option in this analysis, irrespective of vaccine price. Cost data from this study may be useful for other countries wishing to implement a similar programme.
AB - In the first UK study to examine feasibility and acceptability of universal adolescent hepatitis B vaccination, the costs associated with the administration and uptake (80.2 and 89.3% for three doses and at least two doses, respectively), of a three-dose regimen in pupils in Glasgow schools (2001/2002) were measured. These data were used to estimate the economic outlay for the delivery of a routine, ongoing three-dose and two-dose hepatitis B vaccine programme in schools. Vaccine, accounting for almost 70% of the overall costs, was the largest cost item for both the pilot and routine programmes, using either regimen. However, the ongoing, two-dose regimen was the cheapest option in this analysis, irrespective of vaccine price. Cost data from this study may be useful for other countries wishing to implement a similar programme.
KW - Adolescent programme
KW - Cost analysis
KW - Hepatitis B vaccine
UR - http://www.scopus.com/inward/record.url?scp=27744466295&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2005.06.034
DO - 10.1016/j.vaccine.2005.06.034
M3 - Article
C2 - 16099079
AN - SCOPUS:27744466295
SN - 0264-410X
VL - 23
SP - 5624
EP - 5631
JO - Vaccine
JF - Vaccine
IS - 48-49
ER -
